Paclitaxel: New uses for an old drug

Dongshan Zhang, Ruhao Yang, Shixuan Wang, Zheng Dong

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Paclitaxel (Taxol), one of the most important anticancer drugs, has been used for therapy of different types of cancers. Mechanistically, paclitaxel arrests cell cycle and induces cell death by stabilizing microtubules and interfering with microtubule disassembly in cell division. Recently, it has been found that low-dose paclitaxel seems promising in treating non-cancer diseases, such as skin disorders, renal and hepatic fibrosis, inflammation, axon regeneration, limb salvage, and coronary artery restenosis. Future studies need to understand the mechanisms underlying these effects in order to design therapies with specificity.

Original languageEnglish (US)
Pages (from-to)279-284
Number of pages6
JournalDrug Design, Development and Therapy
Volume8
DOIs
StatePublished - Feb 20 2014

Fingerprint

Paclitaxel
Microtubules
Pharmaceutical Preparations
Coronary Restenosis
Limb Salvage
Cell Cycle Checkpoints
Cell Division
Axons
Regeneration
Coronary Vessels
Fibrosis
Cell Death
Inflammation
Kidney
Skin
Liver
Therapeutics
Neoplasms

Keywords

  • Coronary artery restenosis
  • Fibrosis
  • Kidney
  • Limb salvage
  • Taxol inflammation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Paclitaxel : New uses for an old drug. / Zhang, Dongshan; Yang, Ruhao; Wang, Shixuan; Dong, Zheng.

In: Drug Design, Development and Therapy, Vol. 8, 20.02.2014, p. 279-284.

Research output: Contribution to journalArticle

@article{3b86a8153a724079aef8e3b8997350da,
title = "Paclitaxel: New uses for an old drug",
abstract = "Paclitaxel (Taxol), one of the most important anticancer drugs, has been used for therapy of different types of cancers. Mechanistically, paclitaxel arrests cell cycle and induces cell death by stabilizing microtubules and interfering with microtubule disassembly in cell division. Recently, it has been found that low-dose paclitaxel seems promising in treating non-cancer diseases, such as skin disorders, renal and hepatic fibrosis, inflammation, axon regeneration, limb salvage, and coronary artery restenosis. Future studies need to understand the mechanisms underlying these effects in order to design therapies with specificity.",
keywords = "Coronary artery restenosis, Fibrosis, Kidney, Limb salvage, Taxol inflammation",
author = "Dongshan Zhang and Ruhao Yang and Shixuan Wang and Zheng Dong",
year = "2014",
month = "2",
day = "20",
doi = "10.2147/DDDT.S56801",
language = "English (US)",
volume = "8",
pages = "279--284",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Paclitaxel

T2 - New uses for an old drug

AU - Zhang, Dongshan

AU - Yang, Ruhao

AU - Wang, Shixuan

AU - Dong, Zheng

PY - 2014/2/20

Y1 - 2014/2/20

N2 - Paclitaxel (Taxol), one of the most important anticancer drugs, has been used for therapy of different types of cancers. Mechanistically, paclitaxel arrests cell cycle and induces cell death by stabilizing microtubules and interfering with microtubule disassembly in cell division. Recently, it has been found that low-dose paclitaxel seems promising in treating non-cancer diseases, such as skin disorders, renal and hepatic fibrosis, inflammation, axon regeneration, limb salvage, and coronary artery restenosis. Future studies need to understand the mechanisms underlying these effects in order to design therapies with specificity.

AB - Paclitaxel (Taxol), one of the most important anticancer drugs, has been used for therapy of different types of cancers. Mechanistically, paclitaxel arrests cell cycle and induces cell death by stabilizing microtubules and interfering with microtubule disassembly in cell division. Recently, it has been found that low-dose paclitaxel seems promising in treating non-cancer diseases, such as skin disorders, renal and hepatic fibrosis, inflammation, axon regeneration, limb salvage, and coronary artery restenosis. Future studies need to understand the mechanisms underlying these effects in order to design therapies with specificity.

KW - Coronary artery restenosis

KW - Fibrosis

KW - Kidney

KW - Limb salvage

KW - Taxol inflammation

UR - http://www.scopus.com/inward/record.url?scp=84894689998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894689998&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S56801

DO - 10.2147/DDDT.S56801

M3 - Article

C2 - 24591817

AN - SCOPUS:84894689998

VL - 8

SP - 279

EP - 284

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -